ReviewMedScience2026
Paligenosis: dual potential of mature cell plasticity in regeneration and tumorigenesis.
Review in MedScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paligenosis is an emerging model of mature cell plasticity that enables terminally differentiated cells to re-enter the cell cycle and contribute to tissue regeneration following injury. This tightly regulated process involves an initial phase of autophagy-mediated organelle clearance coupled with mechanistic target of rapamycin complex 1 (mTORC1) suppression, followed by mTORC1 reactivation and stemness gene induction that establishes regenerative competence, ultimately culminating in proliferation and lineage restoration. While paligenosis provides an adaptive mechanism to rapidly replenish lost cells in tissues such as the stomach and pancreas, persistent activation under chronic stress or oncogenic signals may drive metaplasia and tumor initiation. Recent evidence further implicates paligenosis-like programs in cancer progression, metastasis, and therapy resistance, underscoring its dual roles in regeneration and disease. Ongoing investigation into the molecular circuitry of paligenosis-including metabolic rewiring, canonical signaling, and epigenetic remodeling-may yield new insights into both tissue repair and oncogenic transformation, offering novel opportunities for therapeutic targeting.
Indexed as
Identifiers
41733879What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.